Compounded preparations are dispensed only on a doctor’s prescription.
Short answer: Minoxidil is studied in men and women with androgenetic alopecia. A 48-week randomised trial in men with androgenetic alopecia reported 45% more hair regrowth with 5% topical minoxidil than with 2% at week 48 (PMID 12196747). A named-patient compounded minoxidil preparation requires a doctor’s prescription and is prepared under Good Compounding Practice (GCP).
What people search for, and why it is a prescription matter
A patient asking about hair loss treatment in Malaysia tends to raise three questions: what minoxidil does, whether it is suitable for them, and how it is obtained. The first two are clinical questions. The third is a prescription question, because a compounded preparation is made for one named patient only, on a doctor’s prescription. Lynnity has no direct-purchase route for compounded preparations, and a patient should not expect a compounded preparation to be supplied without a prescription.
The evidence below explains what the studies report. It does not replace a doctor’s assessment, and it does not describe a Lynnity product.
How minoxidil is placed in the condition
Androgenetic alopecia is the condition this article covers. A 2017 systematic review describes it as “a hair loss disorder mediated by dihydrotestosterone, the potent form of testosterone” (PMID 28396101).
What the trials report in men
The clearest comparison is a 48-week randomised trial of 393 men with androgenetic alopecia. Participants applied 5% topical minoxidil solution, 2% topical minoxidil solution, or a placebo vehicle twice daily (PMID 12196747). The abstract reports that “5% topical minoxidil was significantly superior to 2% topical minoxidil and placebo” in change from baseline in nonvellus hair count, and that the magnitude of the effect was “45% more hair regrowth than 2% topical minoxidil at week 48” (PMID 12196747).
The same trial reports that “an increased occurrence of pruritus and local irritation was observed with 5% topical minoxidil compared with 2% topical minoxidil”, and that topical minoxidil at both strengths “was well tolerated by the men in this trial without evidence of systemic effects” (PMID 12196747).
A 2024 randomised trial in men compared oral minoxidil 5 mg once daily with topical 5% minoxidil twice daily over 24 weeks. Its abstract states that oral minoxidil “did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA” (PMID 38598226). The most common adverse effects in the oral group were hypertrichosis (22 of 45 participants, 49%) and headache (6 of 45, 14%) (PMID 38598226).
What the evidence says in women and across trials
A 2017 systematic review and meta-analysis assessed the effectiveness of nonsurgical treatments of androgenetic alopecia against placebo. Its abstract reports that “all treatments were superior to placebo” across five groups of trials, and that minoxidil is effective in women with androgenetic alopecia (PMID 28396101). The same abstract notes high heterogeneity in most studies (PMID 28396101). The female-specific conclusion rests on one group of trials, 2% minoxidil in women, so the evidence for women is narrower than the evidence for men.
Dosing ranges, with sources
| Study | Route and strength | Schedule | Duration | PMID |
|---|---|---|---|---|
| Randomised trial in men | 5% and 2% topical minoxidil solution | Twice daily | 48 weeks | 12196747 |
| Randomised trial in men | Oral minoxidil 5 mg | Once daily | 24 weeks | 38598226 |
| Randomised trial in men | Topical minoxidil 5% | Twice daily | 24 weeks | 38598226 |
The prescriber sets the strength and route for each named patient.
The forms Lynnity prepares
Lynnity prepares minoxidil as a minoxidil solution, spray or gel, each made to the prescriber’s written specification for one named patient. The form is a prescriber decision.
Limits of the evidence
- The strongest comparisons are in men. One of the cited trials was run at a single clinic, in Brazil (PMID 38598226).
- The 2017 meta-analysis reports high heterogeneity across its studies (PMID 28396101).
- The trials measured change at 24 and 48 weeks (PMID 38598226; PMID 12196747).
Safety and what to report to your doctor
An increased occurrence of pruritus and local irritation was observed with 5% topical minoxidil compared with 2% topical minoxidil (PMID 12196747). Oral minoxidil in the 2024 trial was associated with hypertrichosis and headache (PMID 38598226). Tell your doctor about any new scalp irritation, unwanted hair growth, headache or other change, and give your doctor a full list of the medicines you take.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).
How to get this prescribed
Ask your doctor. A registered doctor in Malaysia decides whether minoxidil is suitable for you, and which route and form to use. A compounded preparation is made only if your doctor sends a prescription.
What the prescription should state. The active (minoxidil), the strength your doctor has chosen, the form (solution, spray or gel), the quantity, the directions and your identity.
How it is sent. Your doctor sends the named-patient prescription with a short formulation brief to the pharmacy. For clinic referrals, see the Kuala Lumpur and Klang Valley referral guide for clinics. Your doctor can also read the guide to compounded minoxidil vehicles for hair clinics before writing the prescription.
Contact. Lynnity’s contact is Vitthia Rama Murti, RPh (RPh 15632). Your doctor can start the conversation through the contact page. See the GCP laboratory page.
The condition page for compounded hair loss treatment is at compounded hair loss treatment.
Frequently asked questions
How does prescription minoxidil work?
Androgenetic alopecia is a hair loss disorder mediated by dihydrotestosterone (PMID 28396101). Your doctor can explain the expected course and the options for your own case.
What does the evidence say about minoxidil in women?
A 2017 meta-analysis reported that all of its groups of trials were superior to placebo and that minoxidil is effective in women with androgenetic alopecia (PMID 28396101). The same abstract notes high heterogeneity across its studies, so the female evidence is narrower than the evidence in men.
Is oral minoxidil the same as topical minoxidil?
The 2024 trial did not show oral minoxidil 5 mg once daily to be superior to 5% topical minoxidil twice daily over 24 weeks (PMID 38598226). It does not establish whether the two routes are equivalent. The choice of route is a decision for your doctor.
What must a prescription for compounded minoxidil state?
It should name minoxidil, the strength your doctor has chosen, the form (solution, spray or gel), the quantity, the directions and your identity.